Many Global Blood Therapeutics, Inc.(GBT) Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock. Global Blood Therapeutics Inc was Initiated by JP Morgan to Overweight on Jan 4, 2017.
Company has reported several Insider transactions to the SEC, on Nov 16, 2016, Charles J Homcy (director) sold 0 shares at 0.00 per share price.On Mar 14, 2016, Jung Choi (officer ) purchased 25,000 shares at 20.00 per share price.On Jan 8, 2016, John Schembri (officer ) purchased 1,500 shares at 21.18 per share price.
Global Blood Therapeutics Inc Last issued its quarterly earnings results on Nov 9, 2016. The company reported $-0.58 EPS for the quarter, beating the analyst consensus estimate by $ 0.01. Analyst had a consensus of $-0.59.During the same quarter in the previous year, the company posted $-0.90 EPS.
Global Blood Therapeutics, Inc. (NASDAQ:GBT) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 1.08 by 6 Brokerage Firm. 5 Wall Street Firms have rated the stock as a strong buys. 1 stock experts have also suggested a buy rating.
Global Blood Therapeutics, Inc. (NASDAQ:GBT) should head towards $57.2 per share according to 5 Analysts in consensus. However, if the road gets shaky, the stock may fall short to $25 per share. The higher price estimate target is at $83 according to the Analysts.
Global Blood Therapeutics, Inc. (NASDAQ:GBT) rose 9.27% or 1.9 points on Tuesday and made its way into the gainers of the day. After trading began at $20.8 the stock was seen hitting $22.55 as a peak level and $20.25 as the lowest level. The stock ended up at $22.4. The daily volume was measured at 1,168,225 shares. The 52-week high of the share price is $27.99 and the 52-week low is $12.24. The company has a market cap of $836 million.
Global Blood Therapeutics, Inc. is a biopharmaceutical company which is engaged in discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. Its product candidate consists of GBT440 is an oral, once-daily prophylactic therapy for sickle cell disease which is in clinical trial. The company in addition to GBT is involved in research and development activities targeted hypoxemic pulmonary disorders, including idiopathic pulmonary fibrosis and hereditary angioedema. Global Blood Therapeutics, Inc. is based in South San Francisco, California.